

As a reminder Quantity Authorizations are suspended

Effective immediately, the approval process for any requests for Quantity Authorizations for Alberta Health-sponsored drug programs in excess of 100-days' supply continue to remain suspended at this time. No exceptions will be made. Non-essential travel continues to be strongly discouraged as per the Government of Canada and Government of Alberta.

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Methotrexate Sodium 25 mg/ml Injection (Unpreserved) (DIN 02182955) manufactured by Pfizer Canada ULC and Methotrexate Sodium 25 mg/ml Injection (Unpreserved) (DIN 02099705) manufactured by Teva Canada Limited, Methotrexate Sodium 10 mg/ml Injection (Unpreserved) (DIN 02182947) manufactured by Pfizer Canada ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pfizer Canada ULC advised Alberta Blue Cross that the shortage of Methotrexate Sodium 25 mg/ml Injection (Unpreserved) (DIN 02182955) has been resolved. As a result, Methotrexate Sodium 10 mg/ml Injection (Unpreserved) (DIN 02182947) will no longer be considered a temporary benefit for the ADBL after **October 26, 2020**. These products were removed from the Critical Supply Product List **September 24, 2020**.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. and Teva Canada Limited that the shortages for pms-Nabilone 1 mg Capsule (DIN 02380919) and Teva-Nabilone 1 mg Capsule (DIN 02384892) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 26, 2020**. The following grouping was removed from the Critical Supply Product List **September 24, 2020**.

NABILONE

1 MG TABLET

00002380919	PMS-NABILONE	PMS	\$ 1.5513
00002384892	TEVA-NABILONE	TEV	\$ 1.5513
00000548375	CESAMET	VCL	\$ 6.9739

... continued from previous page

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage for Mylan-Verapamil SR 240 mg Sustained-Release Tablet (DIN 02450496) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 29, 2020**. The following grouping was removed from the Critical Supply Product List **September 29, 2020**.

VERAPAMIL HCL

240 MG SUSTAINED-RELEASE TABLET

00002246895	APO-VERAP SR	APX	\$ 0.5075
00002450496	MYLAN-VERAP SR	MYP	\$ 0.5075
00000742554	ISOPTIN SR	BGP	\$ 2.2944

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage for Mylan-Verapamil SR 180 mg Sustained-Release Tablet (DIN 02450488) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 2, 2020**. The following grouping was removed from the Critical Supply Product List **September 30, 2020**.

VERAPAMIL HCL

180 MG SUSTAINED-RELEASE TABLET

00002450488	MYLAN-VERAP SR	MYP	\$ 0.5204
00001934317	ISOPTIN SR	BGP	\$ 1.7139

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

